- Stocks
- Pharma & Healthcare
- Denis Chem Lab
Denis Chem Lab share price
NSE: DENISCHEMPharma & HealthcareDrug Manufacturers - Specialty & Generic
Denis Chem Lab at a glance
With a market capitalisation of ₹101 Cr, it ranks 2676th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 9.5% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹47 Cr (+13.0% year on year) and net profit ₹0 Cr (−43.7%), on a standalone basis. Promoters held 38.98% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹101 CrRank 2676 on NSE
- Price to book
- 1.51×FY25
- EPS (TTM)
- ₹6.06to Q4 FY26
- ROE
- 9.5%FY25
- ROCE
- 13.5%FY25
- Debt to equity
- 0.01FY25
- Net profit margin
- 4.7%FY25
- Book value / share
- ₹61.33FY25
- Dividend payout
- 43.0%FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Denis Chem Lab quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹41 Cr | ₹48 Cr | ₹43 Cr | ₹41 Cr | ₹43 Cr | ₹46 Cr | ₹46 Cr | ₹47 Cr |
| Revenue YoY | −2.9% | +5.3% | +6.9% | +3.8% | +4.9% | −3.5% | +6.3% | +13.0% |
| Net profit | ₹2 Cr | ₹4 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹0 Cr |
| Net profit YoY | −22.4% | +39.0% | −45.0% | −74.0% | +19.2% | −37.4% | +88.6% | −43.7% |
| Net margin | 5.0% | 7.4% | 4.1% | 1.7% | 5.7% | 4.8% | 7.3% | 0.9% |
| EPS | ₹1.50 | ₹2.54 | ₹1.27 | ₹0.51 | ₹1.78 | ₹1.60 | ₹2.39 | ₹0.29 |
Denis Chem Lab financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹136 Cr | ₹109 Cr | ₹137 Cr | ₹161 Cr | ₹168 Cr | ₹173 Cr |
| Operating profit | ₹6 Cr | ₹3 Cr | ₹9 Cr | ₹11 Cr | ₹15 Cr | ₹11 Cr |
| Net profit | ₹4 Cr | ₹2 Cr | ₹6 Cr | ₹8 Cr | ₹11 Cr | ₹8 Cr |
| EPS (₹) | ₹3.03 | ₹1.63 | ₹4.51 | ₹5.66 | ₹8.04 | ₹5.82 |
| Cash from operations | ₹13 Cr | ₹8 Cr | ₹17 Cr | ₹16 Cr | ₹18 Cr | ₹12 Cr |
| Total debt | ₹2 Cr | ₹4 Cr | ₹2 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹59 Cr | ₹62 Cr | ₹66 Cr | ₹72 Cr | ₹80 Cr | ₹85 Cr |
Denis Chem Lab shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 38.98% | 38.98% | 38.98% | 38.98% | 38.98% | 38.98% |
| Foreign institutions | — | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Non-institutions | 61.02% | 61.01% | 61.01% | 61.01% | 61.01% | 61.01% |
Denis Chem Lab vs peers
The listed Pharma & Healthcare companies nearest to Denis Chem Lab by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MERCURYLABMercury Labs | — | — | — | ₹102 Cr | — | — |
| VAISHALIVaishali Pharma | ₹7.49 | +2.04% | −30.3% | ₹101 Cr | 124.8 | — |
| CONCORDConcord Drugs | — | — | — | ₹101 Cr | — | — |
| DENISCHEMDenis Chem Lab | — | — | — | ₹101 Cr | — | — |
| FORTISMLRFortis Malar | — | — | — | ₹97 Cr | — | — |
| RAAJMEDIRaaj Medisafe | — | — | — | ₹97 Cr | — | — |
| KHFMKHFM HOSPITALIT | ₹40.90 | +4.87% | −50.1% | ₹95 Cr | — | — |
Ask anything about Denis Chem Lab
Pivot answers on the live chart with evidence you can check, and tests strategies against DENISCHEM's own history. Try: “Why has DENISCHEM moved over the last three months?” · “Backtest a 50-day moving-average crossover on DENISCHEM over five years” · “Compare DENISCHEM with MERCURYLAB on margins and valuation”
Frequently asked questions about Denis Chem Lab
What is the market cap of Denis Chem Lab?
Denis Chem Lab's market capitalisation is ₹101 Cr (₹101 Cr) at the 22 Oct 2026 close, ranking 2676th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Denis Chem Lab?
Return on equity was 9.5% in FY25 and return on capital employed was 13.5% in FY25 (standalone figures).
Is Denis Chem Lab a debt-free company?
Denis Chem Lab is close to debt-free: its debt-to-equity ratio was 0.01 in FY25.
What were Denis Chem Lab's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Denis Chem Lab reported revenue of ₹47 Cr, +13.0% year on year, and net profit of ₹0 Cr, −43.7% year on year.
What is the shareholding pattern of Denis Chem Lab?
As of 30 Jun 2026: promoters 38.98%, foreign institutions 0.01%, non-institutions 61.01%.
Who are Denis Chem Lab's competitors?
The listed Pharma & Healthcare companies closest to Denis Chem Lab by market cap are Mercury Labs, Vaishali Pharma, Concord Drugs, Fortis Malar, Raaj Medisafe and KHFM HOSPITALIT.
Is Denis Chem Lab a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Denis Chem Lab's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DENISCHEM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with D · all NSE stocks · this page as text